These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 8500877

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV, Turbyfill KR.
    Vaccine; 2006 Mar 20; 24(13):2290-301. PubMed ID: 16364513
    [Abstract] [Full Text] [Related]

  • 3. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D.
    Vaccine; 1999 Aug 06; 17(23-24):3109-15. PubMed ID: 10462247
    [Abstract] [Full Text] [Related]

  • 4. Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.
    Clarkson KA, Porter CK, Talaat KR, Frenck RW, Alaimo C, Martin P, Bourgeois AL, Kaminski RW.
    mSphere; 2021 Aug 25; 6(4):e0012221. PubMed ID: 34259559
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D, Orr N, Robin G, Slepon R, Ashkenazi S, Ashkenazi I, Shemer J.
    Clin Diagn Lab Immunol; 1996 Jul 25; 3(4):451-5. PubMed ID: 8807212
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outer Membrane Vesicles Derived from Salmonella enterica Serotype Typhimurium Can Deliver Shigella flexneri 2a O-Polysaccharide Antigen To Prevent Shigella flexneri 2a Infection in Mice.
    Tian H, Li B, Xu T, Yu H, Chen J, Yu H, Li S, Zeng L, Huang X, Liu Q.
    Appl Environ Microbiol; 2021 Sep 10; 87(19):e0096821. PubMed ID: 34319809
    [Abstract] [Full Text] [Related]

  • 11. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
    Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.
    Clin Vaccine Immunol; 2014 Mar 10; 21(3):366-82. PubMed ID: 24403527
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.
    J Infect Dis; 1999 Jun 10; 179(6):1565-8. PubMed ID: 10228084
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis.
    Mitra S, Chakrabarti MK, Koley H.
    Vaccine; 2013 Jun 28; 31(31):3163-73. PubMed ID: 23684822
    [Abstract] [Full Text] [Related]

  • 15. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay.
    Nahm MH, Yu J, Weerts HP, Wenzel H, Tamilselvi CS, Chandrasekaran L, Pasetti MF, Mani S, Kaminski RW.
    mSphere; 2018 Jun 27; 3(3):. PubMed ID: 29898979
    [Abstract] [Full Text] [Related]

  • 16. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, Bialik A, Asato V, Meron-Sudai S, Frankel G, Cohen D, Chilengi R.
    PLoS One; 2021 Jun 27; 16(5):e0252222. PubMed ID: 34043697
    [Abstract] [Full Text] [Related]

  • 17. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G, Cohen D, Orr N, Markus I, Slepon R, Ashkenazi S, Keisari Y.
    J Infect Dis; 1997 May 27; 175(5):1128-33. PubMed ID: 9129076
    [Abstract] [Full Text] [Related]

  • 18. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ, Mulard LA.
    J Immunol; 2009 Feb 15; 182(4):2241-7. PubMed ID: 19201878
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
    Taylor DN, Trofa AC, Sadoff J, Chu C, Bryla D, Shiloach J, Cohen D, Ashkenazi S, Lerman Y, Egan W.
    Infect Immun; 1993 Sep 15; 61(9):3678-87. PubMed ID: 8359890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.